ASIT biotech announced the appointment of Gerd Zettlmeissl as its new Chairman of the Board, Béatrice De Vos having stood down to focus on new projects. Gerd Zettlmeissl, an independent director of ASIT biotech since 2011, was, until that same year, the CEO of Austrian company Intercell AG. Mr. Zettlmeissl accompanied Intercell’s international development, and in particular the global registration of a vaccine against Japanese encephalitis and the signing of strategic partnerships with prominent pharmaceutical companies.